Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03379454 | The Impact of Melanoma and Drug Treatment in the Real World | completed | — | 819 | Vitaccess LtdINDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Prelude TherapeuticsINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) |
| completed |
| Phase 1 / Phase 2 |
| 557 |
| Nektar TherapeuticsINDUSTRY |
| 8 |
| Mar 13, 2023 |
| clinicaltrials |
| NCT02909348 | Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab(PASIP) | completed | — | 25 | Royal Free Hospital NHS Foundation TrustOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02738489 | A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04293289 | Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma | completed | N/A | 10 | Cancer Intelligence Care Systems, Inc.INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05714371 | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | completed | — | 618 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT02032810 | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT01657591 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT01176461 | Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | completed | Phase 1 | 127 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT01993719 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02307149 | Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)(MITCI) | completed | Phase 1 | 50 | ViralyticsINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02565992 | Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)(CAPRA) | completed | Phase 1 | 36 | ViralyticsINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT01456104 | Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03294330 | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer(SPYX) | completed | Phase 3 | 35 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT03843593 | A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | completed | — | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02821182 | A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | completed | Phase 2 | 20 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | completed | Phase 2 | 20 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02434107 | Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)(DeCOG-SLT) | completed | N/A | 483 | University Hospital TuebingenOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT03545334 | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study(LIMIT) | completed | N/A | 93 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT03732560 | A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US | completed | — | 600 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | completed | Phase 1 | 210 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT04675346 | Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors(EUNASS) | completed | — | 252 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02038348 | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study | completed | Phase 2 | 5 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03725449 | Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma | completed | N/A | 116 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases(GRAY-B) | completed | Phase 2 | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02659540 | Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | completed | Phase 1 | 20 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04550000 | Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits | completed | — | 652 | DermTechOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00518206 | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | completed | Phase 2 | 46 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00540566 | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | completed | — | 113 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00199901 | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | completed | Phase 2 | 111 | Ludwig Institute for Cancer ResearchOTHER | 3 | Oct 12, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00142454 | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03834623 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04551352 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | completed | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 6 | Oct 3, 2022 | clinicaltrials |
| NCT03313492 | Modifying Young Adult Skin Cancer Risk and Protective Behaviors(UV4me2) | completed | N/A | 1,746 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02334735 | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | completed | Phase 2 | 36 | Nina BhardwajOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2023source: clinicaltrials